Back to search

Peptide record

TPDB10101

Magainin G Antibacterial Anticancer Antifungal Antiparasitic standard
23 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB10101
Magainin G
Antibacterial Anticancer Antifungal Antiparasitic
Anti-infective peptides Cancer-related peptides
AntiBP3 dbAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF
standard
No
A 23-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, Peptipedia, and other sources, with an available 3D structural model.
C-terminal: Amidation N-terminal: Beta-alanine
Sequence
GIGKFLHSAKKFAKAFVAEIMNS-NH2
Physicochemical Analysis
C116H184N30O29S1
RDCQPTWY
AK
2494.98
10.55
5
1
12
+3
2.23
0.274
80.87
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
3
Residue Composition
number
4
A
0
R
1
N
0
D
0
C
1
E
0
Q
2
G
1
H
2
I
1
L
4
K
1
M
3
F
0
P
2
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 4 R: 0 N: 1 D: 0 C: 0 E: 1 Q: 0 G: 2 H: 1 I: 2 L: 1 K: 4 M: 1 F: 3 P: 0 S: 2 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
23
C116H184N30O29S1
2494.98
10.55
+3
2.23
0.274
Amidation
L
Linear
Beta-alanine
Antibacterial
African clawed frog Xenopus laevis skin Xenopus laevis
Evidence Records 16 records
Evidence 1 Activity

Activity

IC50
IC50=12.5 µM
Anticancer
12.5 µM

Target

Lung Cancer
NCI-H182
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1992

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=10.5 µM
Anticancer
10.5 µM

Target

Lung Cancer
NCI-H526
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1992
Evidence 3 Activity

Activity

IC50
IC50=4.44 µM
Anticancer
4.44 µM

Target

Lung Cancer
NCI-H678
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1992
Evidence 4 Activity

Activity

IC50
IC50=7.23 µM
Anticancer
7.23 µM

Target

Lung Cancer
NCI-H735
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1992
Evidence 5 Activity

Activity

IC50
IC50=11.7 µM
Anticancer
11.7 µM

Target

Lung Cancer
NCI-H841
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1992
Evidence 6 Activity

Activity

IC50
IC50=6.57 µM
Anticancer
6.57 µM

Target

Lung Cancer
NCI-H889
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1992
Evidence 7 Activity

Activity

IC50
IC50=19 µg/ml
Anticancer
19 µg/mL

Target

Lymphoma Cancer
U-937
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 8 Activity

Activity

IC50
IC50=16 µg/ml
Anticancer
16 µg/mL

Target

Leukemia Cancer
8402
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 9 Activity

Activity

IC50
IC50=29 µg/ml
Anticancer
29 µg/mL

Target

Hematopoietic Cancer
SSKT-1
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 10 Activity

Activity

IC50
IC50=38 µg/ml
Anticancer
38 µg/mL

Target

Renal Cancer
Daudi
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 11 Activity

Activity

IC50
IC50=33 µg/ml
Anticancer
33 µg/mL

Target

Leukemia Cancer
MLA
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 12 Activity

Activity

IC50
IC50=25 µg/ml
Anticancer
25 µg/mL

Target

Lymphoma Cancer
Raji
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 13 Activity

Activity

IC50
IC50=37 µg/ml
Anticancer
37 µg/mL

Target

Leukemia Cancer
K-562
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 14 Activity

Activity

IC50
IC50=39 µg/ml
Anticancer
39 µg/mL

Target

Ewing sarcoma
CHP-100
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 15 Activity

Activity

IC50
IC50=42 µg/ml
Anticancer
42 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 16 Activity

Activity

IC50
IC50=47 µg/ml
Anticancer
47 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990